The new antihyperglycemic agents from the sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors class have also shown protective effects against progression of CKD, with reductions of mortality rates when used in combination with RAASi [65]. Here, SLC5A2 is linked to chronic kidney disease.